Literature DB >> 6524966

Treatment of normotensive and hypertensive patients with preterm labor using oral nifedipine, a calcium antagonist.

U Ulmsten.   

Abstract

The calcium antagonist nifedipine was tried on 28 patients with preterm labor. In eight patients the disorder was also accompanied by hypertension. In 80% of the patients delivery could be postponed for more than 3 days during which time corticosteroids were given to accelerate fetal lung maturation. On average, delivery occurred 12 days after start of treatment (delay beyond 36 weeks gestation not being included in the calculations). All patients with increased blood pressure were normotensive within 12 h of the start of treatment. There were no serious maternal or fetal side effects and no perinatal deaths. At 2 and 6 months after delivery all women were normotensive and all children were alive and well.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6524966     DOI: 10.1007/bf02134001

Source DB:  PubMed          Journal:  Arch Gynecol        ISSN: 0170-9925


  13 in total

1.  A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.

Authors:  G C Liggins; R N Howie
Journal:  Pediatrics       Date:  1972-10       Impact factor: 7.124

Review 2.  Pharmacology of labor.

Authors:  K E Andersson; A Forman; U Ulmsten
Journal:  Clin Obstet Gynecol       Date:  1983-03       Impact factor: 2.190

Review 3.  Preterm parturition. Prostaglandin synthetase inhibitors.

Authors:  J R Niebyl
Journal:  Semin Perinatol       Date:  1981-07       Impact factor: 3.300

4.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

5.  Effects of nifedipine on oxytocin- and prostaglandin F2 alpha -induced activity in the postpartum uterus.

Authors:  A Forman; P Gandrup; K E Andersson; U Ulmsten
Journal:  Am J Obstet Gynecol       Date:  1982-11-15       Impact factor: 8.661

6.  Effects of nifedipine on myometrial activity and lower abdominal pain in women with primary dysmenorrhoea.

Authors:  K E Andersson; U Ulmsten
Journal:  Br J Obstet Gynaecol       Date:  1978-02

7.  Treatment of premature labor with the calcium antagonist nifedipine.

Authors:  U Ulmsten; K E Andersson; L Wingerup
Journal:  Arch Gynecol       Date:  1980-01

8.  Inhibition of prostaglandin-induced uterine activity by nifedipine.

Authors:  K E Andersson; I Ingemarsson; U Ulmsten; L Wingerup
Journal:  Br J Obstet Gynaecol       Date:  1979-03

9.  Relaxing effects of Nifedipine on the nonpregnant human uterus in vitro and in vivo.

Authors:  U Ulmsten; K E Andersson; A Forman
Journal:  Obstet Gynecol       Date:  1978-10       Impact factor: 7.661

10.  Intravenous terbutaline and simultaneous beta 1-blockade for advanced premature labor.

Authors:  M G Ross; E Nicolls; P G Stubblefield; J L Kitzmiller
Journal:  Am J Obstet Gynecol       Date:  1983-12-15       Impact factor: 8.661

View more
  5 in total

1.  Anesthetic management of combined caesarean section and pheochromocytoma removal.

Authors:  T Kato; K Hirade
Journal:  J Anesth       Date:  1992-04       Impact factor: 2.078

Review 2.  Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy.

Authors:  P M Kyle; C W Redman
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

Review 3.  A risk-benefit assessment of therapies for premature labour.

Authors:  K Higby; C R Suiter
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

Review 4.  Fetal endoxins and complications of pregnancy.

Authors:  R C Goodlin; E L Makowski
Journal:  West J Med       Date:  1988-05

Review 5.  Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?

Authors:  S M Khedun; B Maharaj; J Moodley
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.